ABSTRACT
Current treatments for human narcolepsy are symptomatically based, with primary effects on dopaminergic transmission for stimulants, adrenergic/serotonergic reuptake for anticataplectic antidepressants, and most likely GABA-B agonistic effects for sodium oxybate (GHB) (1-3). Thanks to renewed interest in this area, novel therapies are emerging. These can be classified into four different broad areas discussed below.
